At Fierce Healthcare, we keep track of all the venture capital being funneled into the health tech and digital health industries.
Our fundraising tracker provides updated coverage of noteworthy digital health and health tech funding rounds, though we'll still profile exciting new companies and larger rounds that catch our eye in depth.
Do you have fundraising news to share? Email Senior Editor Heather Landi at [email protected].
Previous fundraising tracker updates can be found here and here. For news about funding deals from 2023, check out our 2023 Fundraising Tracker.
Digital pathology software startup Proscia picks up $50M
Proscia secured $50 million in funding to advance its AI-driven digital pathology platform.
The funding was led by software investor Insight Partners along with AI Capital Partners (Alpha Intelligence Capital’s U.S. fund) and Triangle Peak Partners. Other investors included Avenue Venture Opportunities Fund, Emerald Development Managers, GPG Healthcare, Fusion Fund, Interwoven Ventures and Razor’s Edge.
The company has raised $130 million to date.
Proscia’s Concentriq platform is designed to accelerate drug discovery, development and diagnostics. The platform has three solutions: Concentriq LS as the central hub for image-based scientific workflows from biomarker discovery to early-stage clinical trials; Concentriq AP enables laboratories to achieve 100% digitization and adopt AI applications; and Concentriq AP-Dx, with FDA 510(k) clearance for primary diagnosis, allows pathologists to view, interpret and manage whole slide images.
Proscia reports strong growth in 2024, now counting 16 of the top 20 pharmaceutical companies among its users, and is on track for more than 22,000 patients to be diagnosed on its Concentriq software platform each day.
The company will use the funds to grow its customer footprint and advance Concentriq, with a focus on extending the platform's core AI capabilities.
Medtech company Sibel Health pockets $30M for monitoring solutions
Sibel Health closed $30 million in series C financing, led by existing investors the Steele Foundation for Hope and Dräger.
The company, a spinout of Northwestern University, will use the funding to accelerate commercial deployment of its ANNE One monitoring platform.
Foundation for Hope previously led Sibel's series B round, adding an additional $20 million investment. Dräger previously led Sibel's series A round, contributing $10 million more in funding.
Enabled by clinical-grade wearable sensors, the ANNE One platform offers wireless monitoring of all vital signs for patients 12 years and older.
Sibel also nabbed its seventh FDA 510(k) clearance "enabling alarms and alerts along with a powerful central station."
"Given the very challenging financing environment, we are ecstatic to see our existing investors fund our entire round given their confidence in our product roadmap and growth trajectory," Steve Xu M.D., co-founder and CEO of Sibel Health, said in a statement.
This month, the company also announced that Northwestern Medicine acquired ANNE One systems to evaluate improvements to both nursing workflow and patient sleep quality with wireless sensors.
Brainomix scores $18M for AI-powered imaging tools for strokes
Brainomix is developing AI-powered imaging tools in stroke and lung fibrosis and picked up a 14 million pound sterling ($18 million) series C investment round.
The round was co-led by prominent health tech investors that include existing investors Parkwalk Advisors, the U.K.'s largest growth EIS fund manager, and the Boehringer Ingelheim Venture Fund (BIVF) along with new investor Hostplus via the IP Group Hostplus Innovation Fund.
A spinout from the University of Oxford, Brainomix now operates in more than 20 countries globally, including the U.S.
It's platform, called Brainomix 360 Stroke, automates validated imaging biomarkers to improve both diagnosis and treatment decisions. The company says its technology has been deployed to more than 300 hospitals, having benefited more than 1.5 million patients.
The company touts results that its Brainomix 360 Stroke was associated with an additional 50% increase in the number of patients receiving mechanical thrombectomy, a life-changing stroke treatment reducing disability.
Brainomix will use the fresh funding to accelerate its commercial expansion into the U.S., where the company has recently secured 10 FDA clearances. It will also advance its portfolio of AI-powered technology in new areas and will expand both its Oxford-based operations and global commercial team.
The company applied its AI expertise to lung fibrosis, with the development and FDA clearance of its Brainomix 360 e-Lung technology to accurately predict the progression of the disease. The company has an ongoing partnership with Boehringer Ingelheim to evaluate the real-world impact of e-Lung to improve the identification and access to treatment for people with progressive lung fibrosis.
Brain.space nabs $11M to bridge the gap between human emotions and AI
Startup Brain.space picked up $11 million in series A funding led by Toyota Ventures, with significant participation by Mangrove Capital Partners and The Group Ventures as well as a $3.5 million non-dilutive grant by the Israel Innovation Authority.
The company developed a noninvasive, easily operable Brain Sensei headset. Requiring only a three-minute setup and minimal training, the Brain Sensei's 115 dry EEG (electroencephalogram) sensors operate autonomously and integrate with additional physiological sensors such as eye trackers, ECG (electrocardiography), GSR (galvanic skin response) and others to collect high-resolution brain data and provide an extensive understanding of a person's mental and cognitive states.
Brain.space is building what it calls a brain-data-as-a-service system, for generative AI mental modeling that better understands—and predicts—human behavior.
The company's patented Brain GPS technology—which maps signals to key functional areas of the brain—applies machine learning modeling to denoise, standardize and automatically label collected brain data for storage and accessibility on the world's most extensive brain cloud, according to the company.
"We are building the largest labeled and standardized Brain Database in the world—with great variety and precision—to design exclusive Mental Modeling that gains actionable, data-based insights about humans' behavior and mental states—such as cognitive load, fatigue, stress, engagement, and focus," said Yair Levy, co-founder and CEO of brain.space, in a statement. "The future of smart, adaptive technology isn't just about automation. It's about understanding each individual's mental state. brain.space is innovating impactful Deep Tech neurotechnology to shape a future in which any human-centric digital system involving an end user will employ Mental Models to create a treatment, a product—an experience—that is specifically tailored to them, and in real time."
Brain.space works with partners in the consumer, health, defense and aerospace industries—from the design phase of research and development—to understand the end user's unique mental state and improve real-time product performance.
In May 2024, the Google AI Startups Fund awarded brain.space with an equity-free grant. And, in January 2025, brain.space completed the Google AI Startups Lab program.